Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Vertex Pharmaceuticals logoVertex Pharmaceuticals VRTX

The company said it completed its acquisition of Alpine Immune Sciences, Inc. ("Alpine") on May 20, 2024 for an equity value of about $5.0 billion.

8-KOther EventsFiled Period of report Summary published (UTC)

Key points

AI summary

  1. The company said it completed its acquisition of Alpine Immune Sciences, Inc. ("Alpine") on May 20, 2024 for an equity value of about $5.0 billion.

  2. It said it completed the acquisition by merging Merger Sub with and into Alpine following the consummation of the Offer, with Alpine continuing as the surviving corporation and a wholly owned subsidiary of Vertex.

  3. Vertex said it entered into an Agreement and Plan of Merger with Adams Merger Sub, Inc. and Alpine on April 10, 2024, which was reported in the Form 8-K filed on April 11, 2024.

  4. The company said it will finalize the accounting treatment for the Alpine acquisition in Q2 2024.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Alpine Immune Sciences Acquisition Completed

The company said it completed its acquisition of Alpine Immune Sciences, Inc. ("Alpine") on May 20, 2024 for an equity value of about $5.0 billion.

Source · Based on the filing body and exhibits

Post-Offer Merger Structure

It said it completed the acquisition by merging Merger Sub with and into Alpine following the consummation of the Offer, with Alpine continuing as the surviving corporation and a wholly owned subsidiary of Vertex.

Source · Based on the filing body and exhibits

Merger Agreement Signing Background

Vertex said it entered into an Agreement and Plan of Merger with Adams Merger Sub, Inc. and Alpine on April 10, 2024, which was reported in the Form 8-K filed on April 11, 2024.

Source · Based on the filing body and exhibits

Accounting Treatment Finalization Timing

The company said it will finalize the accounting treatment for the Alpine acquisition in Q2 2024.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗
Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.